Phase 1b/2a trial shows safety and preliminary efficacy of mezigdomide and elranatamab in patients with relapsed multiple myeloma, suggesting a new treatment direction.
Key Points
Safety and preliminary efficacy assessed for mezigdomide plus elranatamab in relapsed multiple myeloma.
Patients in phase 2 will receive treatment in 28-day cycles based on dose escalation data from phase 1.
Observational study assessing pharmacokinetics and pharmacodynamics alongside treatment efficacy.
Findings may enable innovative treatment approaches for relapsed/refractory multiple myeloma patients.